2024 Revenues ($USD) : $6.40B

Organon, the healthcare company spun off from Merck back in 2021 with a focus on women's health and established medicines, managed to notch its third straight year of constant currency revenue growth in 2024. Total revenue landed at $6.4 billion, up 2.2% as reported, or a 3% bump on a constant currency basis.

But that top-line gain didn't translate to the bottom line. Net income actually slid 16% to $864 million, dragging profit margins down from 16% to 14%. Earnings per share also took a hit, missing analyst forecasts.

Digging into the segments, based on Q4 performance: its women's health unit came in flat. Strong growth from NEXPLANON got cancelled out by dips in the fertility portfolio and NUVARING. Biosimilars revenue tumbled 18%, hit by tender timing issues and pricing pressure, although the newly launched Hadlima showed it was continuing to ramp up. Established Brands, Organon's biggest piece, edged up 2%. Contributions from Emgality and Vtama helped soften the blow from Atozet losing exclusivity in key markets.

So, despite headwinds like that Atozet patent cliff, Organon showed some resilience just by keeping the overall revenue growing. Looking ahead to 2025, the company is guiding for potential continued constant currency revenue growth. But it's clearly emphasizing cost discipline, aiming to keep adjusted EBITDA margins at 31.0% or better (excluding R&D spend).

Analysts seem to be flagging the mixed financial results here. Key things to monitor will be profitability trends, how NEXPLANON holds up, the pace of Hadlima uptake, and how the company manages any further patent expirations. Still, its distinct focus on women's health is noted.